AtriCure Inc. (ATRC)

27.86
0.05 0.18
NASDAQ : Health Technology
Prev Close 27.91
Open 27.93
Day Low/High 27.51 / 28.76
52 Wk Low/High 14.88 / 30.96
Volume 125.42K
Avg Volume 172.10K
Exchange NASDAQ
Shares Outstanding 35.04M
Market Cap 1.06B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insider Bets Paying Off At ATRC As New 52-Week High Reached

Insider Bets Paying Off At ATRC As New 52-Week High Reached

In trading on Wednesday, shares of AtriCure Inc touched a new 52-week high of $25.16/share. That's a 69.09% rise, or $10.28 per share from the 52-week low of $14.88 set back on 02/09/2018.

AtriCure And Baheal Group Establish Partnership And China Distribution Agreement

AtriCure And Baheal Group Establish Partnership And China Distribution Agreement

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure's surgical...

ATRC: Insiders Vs. Shorts

ATRC: Insiders Vs. Shorts

The most recent short interest data was recently released for the 05/15/2018 settlement date, and AtriCure Inc is one of the most shorted stocks of the Russell 3000, based on 15.11 "days to cover" versus the median component at 4.39. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

AtriCure Reports First Quarter 2018 Financial Results

AtriCure Reports First Quarter 2018 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2018 financial results.

AtriCure To Announce First Quarter 2018 Financial Results

AtriCure To Announce First Quarter 2018 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2018 financial...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AtriCure To Present At The Needham & Company's 17th Annual Healthcare Conference

AtriCure To Present At The Needham & Company's 17th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham &...

AtriCure Reports Fourth Quarter And Full Year 2017 Financial Results

AtriCure Reports Fourth Quarter And Full Year 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter and full year 2017 financial results.

AtriCure Launches The AtriClip® FLEX•V™ Device In The United States

AtriCure Launches The AtriClip® FLEX•V™ Device In The United States

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the AtriClip FLEX•V™ Left...

AtriCure Names Scott Drake Board Chairman

AtriCure Names Scott Drake Board Chairman

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Scott Drake has been named Board Chairman,...

AtriCure To Announce Fourth Quarter And Full Year 2017 Financial Results

AtriCure To Announce Fourth Quarter And Full Year 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2017...

AtriCure is Now Oversold (ATRC)

AtriCure is Now Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Reports Preliminary Results For Fourth Quarter And Full Year 2017

AtriCure Reports Preliminary Results For Fourth Quarter And Full Year 2017

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and...

AtriCure To Present At The 36th Annual JP Morgan Healthcare Conference

AtriCure To Present At The 36th Annual JP Morgan Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 36 th Annual JP Morgan...

AtriCure is Now Oversold (ATRC)

AtriCure is Now Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AtriCure To Present At The Piper Jaffray 29th Annual Healthcare Conference

AtriCure To Present At The Piper Jaffray 29th Annual Healthcare Conference

AtriCure, Inc. ( Nasdaq:ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 29 th...

AtriCure Becomes Oversold (ATRC)

AtriCure Becomes Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Reports Third Quarter 2017 Financial Results

AtriCure Reports Third Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2017 financial results.

AtriCure To Present At The Stifel Healthcare Conference

AtriCure To Present At The Stifel Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Stifel Healthcare...

AtriCure To Announce Third Quarter 2017 Financial Results

AtriCure To Announce Third Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2017 financial...

AtriCure Announces U.S. Launch Of The AtriClip® PRO•V™ Device

AtriCure Announces U.S. Launch Of The AtriClip® PRO•V™ Device

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the AtriClip PRO•V™ Left Atrial...

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure To Present At The Morgan Stanley Global Healthcare Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global...

ATRC Crosses Above Average Analyst Target

ATRC Crosses Above Average Analyst Target

In recent trading, shares of AtriCure Inc have crossed above the average analyst 12-month target price of $23.50, changing hands for $23.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AtriCure Reports Second Quarter 2017 Financial Results

AtriCure Reports Second Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2017 financial results.

AtriCure To Present At The Canaccord Genuity 37th Annual Growth Conference

AtriCure To Present At The Canaccord Genuity 37th Annual Growth Conference

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity...

AtriCure Announces Hiring Of Chief Technology Officer

AtriCure Announces Hiring Of Chief Technology Officer

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology...

AtriCure To Announce Second Quarter 2017 Financial Results

AtriCure To Announce Second Quarter 2017 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2017 financial...

TheStreet Quant Rating: C- (Hold)